SCHEMBL14136240

SCHEMBL14136240

COc1ccc(C2CC(c3ccc(NS(=O)(=O)c4ccc(C)cc4)cc3)=NN2C(C)=O)cc1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 2/20 0.72
▸ CA12 O43570 4/20 0.65
▸ CA1 P00915 4/20 0.65
▸ CA2 P00918 4/20 0.65
▸ CA9 Q16790 4/20 0.65
▸ CA4 P22748 1/20 0.65
▸ MAOA P21397 2/20 0.65
▸ MAOB P27338 2/20 0.65
▸ NPC1 O15118 2/20 0.64
▸ RAB9A P51151 2/20 0.64
▸ MEN1 O00255 2/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ PKM P14618 2/20 0.62
▸ EGFR P00533 1/20 0.62
▸ ALOX12 P18054 1/20 0.59
▸ BCL2 P10415 1/20 0.59
▸ BECN1 Q14457 1/20 0.59
▸ ACHE P22303 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14058333 0.96 PTGS2 (0.77) PTGS2CA12CA1CA2CA9
SCHEMBL14136234 0.93 PTGS2 (0.76) PTGS2CA12CA1CA2CA9
SCHEMBL14058030 0.92 PTGS2 (0.71) PTGS2CA12CA1CA2CA9
SCHEMBL14058045 0.92 PTGS2 (0.71) PTGS2CA12CA1CA2CA9
SCHEMBL14058334 0.92 PTGS2 (0.71) PTGS2CA12CA1CA2CA9
SCHEMBL14058704 0.92 PTGS2 (0.71) PTGS2CA12CA1CA2CA9
SCHEMBL14058605 0.92 PTGS2 (0.71) PTGS2CA12CA1CA2CA9
SCHEMBL14058025 0.92 NPC1 (0.78) PTGS2CA12CA1CA2CA9
SCHEMBL14058705 0.92 PTGS2 (0.71) PTGS2CA12CA1CA2CA9
SCHEMBL14058690 0.91 NPC1 (0.74) PTGS2CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 PTGS2 1275/4885CA12 4776/4885CA1 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback